6:11 PM
 | 
Sep 25, 2013
 |  BC Extra  |  Clinical News

Oncothyreon jumps on tecemotide Phase III plans

Oncothyreon Inc. (NASDAQ:ONTY) jumped $0.38 (21%) to $2.18 on Wednesday after Merck KGaA (Xetra:MRK) said it will begin the Phase III START2 trial of tecemotide ( L-BLP25) to treat non-small cell lung cancer (NSCLC) despite the compound missing the primary endpoint in the Phase III START...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >